Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Halt!!

<< Previous

Bullboard Posts

Next >>

Comment by DSMed77on May 14, 2020 11:11am

114 Views

Post# 31027671

RE:RE:RE:RE:RE:Halt!!

I am invested in LITT and we have been halted for almost a month.

Chritters wrote: Wrong!!! Ive been in stocks that have taken up to 3 days.

RoyMax123 wrote: It usually don't take that long for tsxv / IIROC to approve so it's probably another fishy deal like the last one.

TrakleOfCheese wrote: Rob answered to someone on the Facebook group yesterday:
Bob’s responded to my email this afternoon, I asked if the news would be released today: “We are waiting for TSXV and IIROC approval of the press release.”